Alzheimer's Testing with Breakthrough Blood Analysis
Veravas revolutionizes Alzheimer's diagnostics with VeraBIND technology, offering clear yes/no results instead of traditional gray-area testing. Their blood-based method measures active tau pathology, potentially eliminating the need for costly PET scans and lumbar punctures.
Veravas has developed a groundbreaking approach to Alzheimer's detection. Their VeraBIND technology measures active tau pathology in blood samples, providing clear yes/no results rather than ambiguous ranges.
The technology stems from collaboration with renowned Alzheimer's researcher Dr. Khalid Iqbal. "We're asking if a biomarker is pathologically active," explains Carroll Soldo, distinguishing their method from standard blood tests. "We capture and purify this biomarker to characterize its binding interaction."
This advancement helps patients avoid:
- Expensive PET scans
- Painful lumbar punctures
- Unclear test results requiring additional procedures
The leadership brings deep expertise to this project. CEO John Forrest has FDA approval experience and a track record of successful exits, while Soldo developed the core IP behind VeraBIND.
Looking ahead, Veravas plans to expand beyond neurodegenerative diseases. Their platform shows promise for cancer detection and saliva diagnostics, targeting their goal: making every diagnostic test accurate on the first try.
